Ask the Expert: Thomas A. Rando, MD, PhD on Young Blood, Biomarkers and Aging

A Q&A with Thomas A. Rando, M.D., Ph.D. on Young Blood, Biomarkers, and Aging

Read full article

Rejuvenating our cells can make them more prone to cancer

Researcher Thomas Rando, from Stanford University, talks about efforts to increase the number of healthy years we live.

Read full article

PROFESSORDepartment of Neurology and Neurological Sciences
Stanford University School of Medicine
DIRECTORThe Glenn Center for the Biology of Aging
Stanford University School of Medicine
DIRECTORRR&D Center of Excellence / REAP
VA Palo Alto Health Care System
CHIEF
Neurology Service
VA Palo Alto Health Care System
DEPUTY DIRECTORStanford Center on Longevity (SCL)
Stanford University

Is it real or science fiction to dream of being able to treat… getting old? In this episode, we discuss with Dr. Thomas Rando from Stanford (who directs the Glenn Center for the Biology of Aging), Kristen Fortney, CEO of BioAge, and a16z’s general partner Vijay Pande where we are in the field of “geroscience” — the idea of studying aging itself, and aging as the root risk for all aging related disease. Far from science fiction, recent discoveries have given us a whole crop of promising breakthroughs to treat aging, such as parabiosis (young blood infused into old blood), senolytics, and rapamycin, and more.